tetano
Editor, Senior Moderator
J Med Virol
. 2022 Apr 21.
doi: 10.1002/jmv.27801. Online ahead of print.
Generation and Characterization of Humanized Synergistic Neutralizing Antibodies against SARS-CoV-2
Jiazheng Guo[SUP] 1 [/SUP], Jun Zhang[SUP] 1 [/SUP], Peng Du[SUP] 1 [/SUP], Jiansheng Lu[SUP] 1 [/SUP], Lei Chen[SUP] 1 [/SUP], Ying Huang[SUP] 1 [/SUP], Yunzhou Yu[SUP] 1 [/SUP], Qing Xie[SUP] 1 [/SUP], Rong Wang[SUP] 1 [/SUP], Zhixin Yang[SUP] 1 [/SUP]
Affiliations
Abstract
The emerging coronavirus, severe acute respiratory syndrome coronavirus 2 （SARS-CoV-2), is the causative agent of coronavirus disease 2019 (COVID-19), which has become a severe threat to global public health and local economies. In this study, several single chain antibody fragments (scFvs) that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein were identified and used to construct human-mouse chimeric antibodies and humanized antibodies. These antibodies exhibited strong binding to RBD and neutralization activity towards a SARS-CoV-2 pseudovirus. Moreover, these antibodies recognize different RBD epitopes and exhibit synergistic neutralizing activity. These provide candidate to combination use or bispecific antibody to potential clinical therapy for COVID-19. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; humanized neutralizing antibody; pseudovirus system; synergistic neutralizing activity.
. 2022 Apr 21.
doi: 10.1002/jmv.27801. Online ahead of print.
Generation and Characterization of Humanized Synergistic Neutralizing Antibodies against SARS-CoV-2
Jiazheng Guo[SUP] 1 [/SUP], Jun Zhang[SUP] 1 [/SUP], Peng Du[SUP] 1 [/SUP], Jiansheng Lu[SUP] 1 [/SUP], Lei Chen[SUP] 1 [/SUP], Ying Huang[SUP] 1 [/SUP], Yunzhou Yu[SUP] 1 [/SUP], Qing Xie[SUP] 1 [/SUP], Rong Wang[SUP] 1 [/SUP], Zhixin Yang[SUP] 1 [/SUP]
Affiliations
- PMID: 35451094
- DOI: 10.1002/jmv.27801
Abstract
The emerging coronavirus, severe acute respiratory syndrome coronavirus 2 （SARS-CoV-2), is the causative agent of coronavirus disease 2019 (COVID-19), which has become a severe threat to global public health and local economies. In this study, several single chain antibody fragments (scFvs) that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein were identified and used to construct human-mouse chimeric antibodies and humanized antibodies. These antibodies exhibited strong binding to RBD and neutralization activity towards a SARS-CoV-2 pseudovirus. Moreover, these antibodies recognize different RBD epitopes and exhibit synergistic neutralizing activity. These provide candidate to combination use or bispecific antibody to potential clinical therapy for COVID-19. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; humanized neutralizing antibody; pseudovirus system; synergistic neutralizing activity.